Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04435821 | PET/MRI in the Diagnosis of Pediatric Chronic Pain | PHASE1 | COMPLETED | 5 | — | — | Nov 19, 2020 | Oct 31, 2024 | Jun 6, 2025 | 1 | United States |
Biodistribution of \[18F\]FTC-146 represented as Standardized Uptake Value max (SUVmax) in pain patients.
| Arm | Type | Description |
|---|---|---|
| Pediatric Chronic Pain Patients | EXPERIMENTAL | Individuals 11-18 years old, with chronic pain (lasting at least 2 months). |
| Name | Type | Description |
|---|---|---|
| [18F]FTC-146 | DRUG | Participants will be injected with 0.08 mCi/kg \[18F\]FTC-146. A whole-body PET/MRI scan will be performed after injection. |
Inclusion Criteria: * 11-18 years old. * Chronic pain (nociceptive, neuropathic or mixed pain) lasting at least 2 months. * Pain level of at least 4/10 on a 0-10 Comparative Pain Scale (reported at time of screening). * Covid Vaccination status: Vaccinated or unvaccinated subjects who received a ne...